Alpha Tau Medical Beheer

Beheer criteriumcontroles 4/4

De CEO Alpha Tau Medical is Uzi Sofer, benoemd in Jan2015, heeft een ambtstermijn van 9.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 630.00K, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 16.47% van de aandelen van het bedrijf, ter waarde $ 26.43M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 7.8 jaar.

Belangrijke informatie

Uzi Sofer

Algemeen directeur

US$630.0k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	9.8yrs
Eigendom CEO	16.5%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	7.8yrs

Recente managementupdates

Recent updates

Alpha Tau Medical (NASDAQ:DRTS) Has Debt But No Earnings; Should You Worry?

May 25

Alpha Tau Medical (NASDAQ:DRTS) Is In A Good Position To Deliver On Growth Plans

Nov 08

Analyse CEO-vergoeding

Hoe is Uzi Sofer's beloning veranderd ten opzichte van Alpha Tau Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$30m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$29m
Dec 31 2023	US$630k	US$630k	-US$29m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$3m	US$628k	-US$34m

Compensatie versus markt: De totale vergoeding ($USD 630.00K ) Uzi } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Uzi is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Uzi Sofer (54 yo)

9.8yrs

Tenure

US$630,000

Compensatie

Mr. Uzi Sofer serves as Chief Executive Officer and Chairman at Alpha Tau Medical LTD (Alternate name Healthcare Capital Corp.) since 2015. He founded Brainsway Ltd., in 2006 and served as its Chief Execut...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Uzi Sofer	CEO & Chairman	9.8yrs	US$630.00k	16.47% $ 26.4m
Raphi Levy	Chief Financial Officer	5.8yrs	US$424.00k	0% $ 0
Amnon Gat	Chief Operations Officer	6.8yrs	US$340.00k	0.098% $ 157.2k
Peter Melnyk	Chief Commercial Officer	2.2yrs	US$376.00k	0% $ 0
Robert Den	Chief Medical Officer & Member of Scientific Advisory Board	5.2yrs	US$401.00k	0% $ 0
Ronen Segal	Chief Technology Officer	5.8yrs	US$705.00k	0% $ 0
Yona Keisari	Chief Scientific Officer & Member of Scientific Advisory board	5.2yrs	geen gegevens	0.72% $ 1.2m
Rebecca Becker	Vice President of legal	no data	geen gegevens	geen gegevens
Itzhak Kelson	Chief Physics Officer & Member of Scientific Advisory Board	8.8yrs	geen gegevens	1.9% $ 3.0m
Yael Zeiger	Corporate Controller	no data	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DRTS is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Uzi Sofer	CEO & Chairman	9.8yrs	US$630.00k	16.47% $ 26.4m
Robert Den	Chief Medical Officer & Member of Scientific Advisory Board	no data	US$401.00k	0% $ 0
Yona Keisari	Chief Scientific Officer & Member of Scientific Advisory board	5.2yrs	geen gegevens	0.72% $ 1.2m
Itzhak Kelson	Chief Physics Officer & Member of Scientific Advisory Board	no data	geen gegevens	1.9% $ 3.0m
Ruth Alon	Independent Director	2.7yrs	geen gegevens	0% $ 0
Alan Adler	Independent Director	6.8yrs	geen gegevens	0% $ 0
David Milch	Independent Director	2.7yrs	geen gegevens	0.41% $ 662.8k
Meir Jakobsohn	Independent Director	8.8yrs	geen gegevens	0.11% $ 172.1k
Michael Zelefsky	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
S. Blumenfeld	Independent Director	8.8yrs	geen gegevens	0.067% $ 108.1k
Michael Avruch	Director	8.8yrs	geen gegevens	2.17% $ 3.5m
Aron Popovtzer	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

7.8yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DRTS wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).

Alpha Tau Medical Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Alpha Tau Medical Ltd., Annual General Meeting, Dec 17, 2024

Board Member notifies of intention to sell stock

Board Member notifies of intention to sell stock

Alpha Tau Medical Ltd. Announces Stephen M. Hahn Joins Scientific Advisory Board

Alpha Tau Medical Ltd., Annual General Meeting, Nov 01, 2023

No independent directors

Recent updates

Alpha Tau Medical Ltd., Annual General Meeting, Dec 17, 2024

Alpha Tau Announces Acceptance into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha Dart® for Patients with Recurrent Glioblastoma Multiforme

Alpha Tau Medical Ltd. Treats First Patient with Recurrent Lung Cancer

Alpha Tau Medical Ltd. Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-To-Treat Superficial Cancers

Alpha Tau Medical (NASDAQ:DRTS) Has Debt But No Earnings; Should You Worry?

Alpha Tau Medical Ltd. Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

Price target decreased by 14% to US$9.25

Board Member notifies of intention to sell stock

Board Member notifies of intention to sell stock

Alpha Tau Medical Ltd. Announces Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Alpha Tau Medical Ltd. Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Alpha Tau Medical (NASDAQ:DRTS) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Alpha Tau Medical Ltd. Announces Stephen M. Hahn Joins Scientific Advisory Board

Alpha Tau Medical Ltd., Annual General Meeting, Nov 01, 2023

Alpha Tau Medical Ltd. Treats First Patient with Advanced Inoperable Pancreatic Cancer At Israel's Hadassah Medical Center

Alpha Tau Medical Ltd. Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

Alpha Tau Medical Ltd. Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

Price target decreased by 13% to US$15.00

Price target decreased to US$18.00

No independent directors

Alpha Tau Medical Ltd., Annual General Meeting, Nov 02, 2022

Alpha Tau Medical Ltd. Announces the Acceptance of Two Pre-Clinical Studies

Alpha Tau Medical Ltd. Appoints Peter Melnyk as Chief Commercial Officer

Alpha Tau director gives up board seat to take up chief commercial officer role

Alpha Tau Medical GAAP EPS of -$0.03

Alpha Tau Medical Ltd. Announces Treatment of First Prostate Cancer Patient with Alpha DaRT

Alpha Tau Medical Ltd. Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at Its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site

Alpha Tau Medical Ltd. Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT(TM) in Recurrent Cutaneous SCC

Alpha Tau Medical Ltd. Announces Resignation of Gary Leibler from Board of Directors and Audit Committee

Alpha Tau Medical Ltd. Announces Treatment of First Alpha DaRT Patients in France as Part of Alpha DaRT(TM) Multicenter Skin Cancer Trial

No independent directors

Alpha Tau: Treating Cancer With Precision Alpha Radiation

No independent directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd